GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects cover art

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

Listen for free

View show details

About this listen

 Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February 11, these GLP-1 drugs, including semaglutide in Ozempic and tirzepatide in Mounjaro, lead to average weight losses of 11 to 16 percent over one to two years in people with obesity, far outperforming placebos in trials with thousands of participants. Tirzepatide achieved about 16 percent reduction after 12 to 18 months, while semaglutide hit roughly 11 percent after 24 to 68 weeks, with benefits lasting as long as treatment continues. However, most studies were funded by drugmakers, long-term safety data remain limited, and common side effects like nausea affect many users.

A Rutgers Health study published this week in the Journal of Medical Internet Research, as reported by Healthline on February 16, reveals that Ozempic users often prioritize weight loss over these side effects. Researchers analyzed online reviews and found that 67 percent reported reduced appetite and cravings alongside weight loss, making them satisfied enough to continue despite gastrointestinal issues in 62 percent of cases. Lead author Abanoub Armanious noted that everyday users value efficacy highly, even tolerating discomfort that prompts some to stop other treatments. Bariatric surgeon Mir Ali added that patients paying out of pocket show strong motivation, often seeking remedies for nausea rather than quitting.

Novo Nordisk announced on February 17 that a new clinical study demonstrated people lost about 21 percent of their body weight on average with their obesity treatment, highlighting ongoing advancements in GLP-1 therapies. No fresh comments from Oprah Winfrey on Ozempic emerged this week, though her past support underscores the cultural buzz around these medications.

Experts like Juan Franco from Heinrich Heine University emphasize the excitement after decades without effective options, but call for independent long-term studies on heart health, quality of life, and weight regain after stopping. Access issues persist due to high costs, though semaglutide patents expire this year, potentially lowering prices.

Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.